A phase 1 dose-escalation trial enrolled children and young adults with B-cell malignancies, with the primary objective of evaluating toxicity and dose-finding for a novel dual-antigen CAR T-cell therapy. Five Cogstate digital tests were selected for the study. Results demonstrated the cognitive safety of CAR T-cell therapy in this population. Researchers gathered conclusive data and found Cogstate assessments easy to administer and feasible to use in this patient population. (Shalabi, et al, https://doi.org/10.1182/blood.2022015795 ) (YouTube Summary)
Case Examples of Cogstate Oncology Solutions in Action
Demonstrating Cognitive Safety of CAR T-Cell Therapy
Measuring Neurocognitive Effects of Oncology Treatments in Pediatrics
A multi-national consortium on childhood cancers required cognitive assessments to better understand the effects of those cancers on brain health and brain development. In previous trials there had been high rates of missing data. Cogstate provided digital cognitive assessments for a large trial in pediatric acute lymphoblastic leukemia. More than 86% of patients successfully completed the Cogstate battery, a number substantially greater than those obtained in previous trials with paper and pencil assessments. In addition, the study team noted higher patient satisfaction with the testing. (Hardy et al, INS, 2014) (YouTube Summary)